Updated data from the ADVANCE II Phase 2 trial presented at ASH demonstrate durable survival of AML patients treated with vididencel

What we doOur approachPipelineTechnologyPublications
About usExecutive ManagementBoard of DirectorsScientific Advisory Board
News & eventsPress releasesEventsInterviews
Investors
Careers

Back
Updated data from the ADVANCE II Phase 2 trial presented at ASH demonstrate durable survival of AML patients treated with vididencel
 8:00:00 AM

Keep reading
Mendus and UMCG announce positive topline data from the ALISON trial with vididencel in ovarian cancerRead